Drug Trial Radar · NCT06805656
Multi Interventional Approaches to Mitigate HIV Reservoirs for the Sustained HIV Remission Without Antiretrovirals
Last checked: Nov 20, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Jul 15, 2026
Primary completion
Mar 1, 2027
Study completion Jun 1, 2028
Sponsor
- Lead sponsor
- Federal University of São PauloAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Conselho Nacional de Desenvolvimento Científico e Tecnológico; Weill Medical College of Cornell University; Fundação de Amparo à Pesquisa do Estado de São Paulo
- First posted
- Feb 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A modern and urgent challenge in fighting HIV infection is to achieve sustained HIV remission without the use of antiretrovirals. The investigators' preliminary data indicate that the use of combined strategies to mitigate the HIV proviral reservoir size among individuals with suppressive antiretroviral treatment achieved unprecedented results in the reduction of HIV DNA present in these cells and in the reduction of CD4 + and CD8 + T cell activation. Combined interventions include intensified antiretroviral treatment to mitigate residual HIV replication, use of a histone deacetylase inhibitor to interrupt viral latency, use of an anti-proliferative medication to reduce long-lived T cells that harbor HIV and a personalized dendritic cell therapy vaccine to eliminate cells with latent HIV infection or cells present in viral sanctuaries. Due to the good results obtained in the exploratory stage of the project, the investigators propose to expand it by recruiting a larger number of patients to confirm the previously obtained results and to generate new insights related to the mechanisms involved in viral latency, latency disruption and the effects of analytical treatment interruption of antiretrovirals among patients undergoing all above mentioned interventions.
Conditions
- Hiv
- HIV I Infection
Interventions
MaravirocDrug
antiretroviral intensification
DolutegravirDrug
antiretroviral intensification
Dendritic Cell VaccineBiological
therapeutic vaccination
AuranofinDrug
purging
Sirtuin Histone deacetylase inhibitorDrug
latency disruption
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evolution of viral load of HIV RNA over the time frame of studyTime frame: baseline, weeks 12, 24, 36 and 48 and every 3 weeks after the antiretroviral ATI up to 36 months after antiretroviral ATI
- Evolution of total DNA and episomal HIV in PBMCsTime frame: baseline, weeks 12, 24, 36 and 48 and every 3 weeks after the antiretroviral ATI up to 36 months after antiretroviral ATI
- Evolution of cell-associated HIV RNA in PBMCs over the study time frameTime frame: baseline, weeks 12, 24, 36 and 48 and every 3 weeks after the antiretroviral ATI up to 36 months after antiretroviral ATI
- Evolution of total DNA and episomal HIV DNA in lymphoid tissue (rectal biopsy)Time frame: baseline, week 48, after resurgence of viremia in the analytical interruption of antiretrovirals, or after 24 and 96 weeks after analytical interruption of antiretrovirals.
- Evolution of the HIV DNA sequence of the V3 region of gp 120, protease, reverse transcriptase and integrase regions of the pol gene, and of the gag geneTime frame: baseline, week 24, week 48, after resurgence of viremia after ATI and before reintroduction of ART
- Evolution of the HIV RNA sequence of the V3 region of gp 120, protease, reverse transcriptase and integrase regions of the pol gene, and of the gag geneTime frame: baseline, week 24, week 48, after resurgence of viremia after ATI and before reintroduction of ART
- Evolution of CD4 + and CD8 + T lymphocyte countTime frame: baseline, weeks 12, 24, 36 and 48 and every 3 weeks after the antiretroviral ATI up to a total of 36 months after ATI.
- Evolution of percentages of CD38 and HLA DR in CD4 + and CD8 + T lymphocytesTime frame: baseline, weeks 12, 24, 36 and 48 and every 3 weeks after the antiretroviral ATI up to 36 months after antiretroviral ATI
- Evolution of plasma cytokines IL-2, IL-4, IL-6, IL-10, IL-17, TNF and IFN-γTime frame: baseline, weeks 12, 24, 36 and 48 and every 3 weeks after the antiretroviral ATI up to 36 months after antiretroviral ATI
- Changes in bacterial translocation levels by quantification of plasma LPS levelsTime frame: baseline, weeks 12, 24, 36 and 48 and every 3 weeks after the antiretroviral ATI up to 36 months after antiretroviral ATI
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CCDI
São Paulo, São Paulo, Brazil · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.